Earnings ·
Turn Therapeutics reports Q3 net loss of $0.21 per share, cash runway into Q3 2027
TTRXTurn Therapeutics Inc.
Turn Therapeutics Inc. reported a third-quarter 2026 net loss of $6.2 million, or $0.21 per basic and diluted share, compared to a $1.9 million loss in the prior-year period. The company held $10.4 million in cash as of September 30, 2026, which management expects will fund operations into the third quarter of 2027. General and administrative expenses decreased to $1.4 million from $1.8 million, while research and development expenses rose to $0.6 million due to continued spending on the Phase 2b atopic dermatitis trial. The company also announced that former CDC Director Robert R. Redfield has been appointed Chief Scientific Officer and provided updates on its GX-03 clinical programs. Turn Therapeutics Inc. is a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases.